Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Rutgers, The State University of New Jersey
Copenhagen University Hospital at Herlev
Incyte Corporation
Jules Bordet Institute
Centre Oscar Lambret
Eastern Cooperative Oncology Group
Eli Lilly and Company
City of Hope Medical Center
Pfizer
Fondazione del Piemonte per l'Oncologia
National Taiwan University Hospital
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
University of California, San Francisco
Vejle Hospital
UNC Lineberger Comprehensive Cancer Center
RemeGen Co., Ltd.
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
NYU Langone Health
Institute of Oncology Ljubljana
Vanderbilt University Medical Center
The Netherlands Cancer Institute
M.D. Anderson Cancer Center
Xencor, Inc.
City of Hope Medical Center
M.D. Anderson Cancer Center
Blokhin's Russian Cancer Research Center
San Raffaele University
NRG Oncology
NRG Oncology
Cartography Biosciences
University of Sao Paulo
MedImmune LLC
Eastern Cooperative Oncology Group
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pfizer
Kaiser Permanente